BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33030596)

  • 1. Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol.
    Cloyd JM; Hyman S; Huwig T; Monsour C; Santry H; Wills C; Tsung A; Bridges JFP
    Support Care Cancer; 2021 Jun; 29(6):3009-3016. PubMed ID: 33030596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma.
    Ruff SM; Stevens L; Bressler L; Khatri R; Sarna A; Ejaz AM; Dillhoff M; Pawlik TM; Rose K; Cloyd JM
    J Surg Oncol; 2024 Mar; 129(4):775-784. PubMed ID: 38063046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
    Hamad A; Crossnohere N; Ejaz A; Tsung A; Pawlik TM; Sarna A; Santry H; Wills C; Cloyd JM
    Pancreas; 2022 Jul; 51(6):657-662. PubMed ID: 36099500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study.
    Stevens L; Brown ZJ; Zeh R; Monsour C; Wells-Di Gregorio S; Santry H; Ejaz AM; Pawlik TM; Cloyd JM
    World J Gastrointest Oncol; 2022 Jun; 14(6):1175-1186. PubMed ID: 35949220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
    Schreiber L; Zeh R; Monsour C; Ejaz A; Tsung A; Pawlik TM; Miller E; Noonan A; Krishna SG; Santry H; Cloyd JM
    HPB (Oxford); 2022 Jun; 24(6):833-840. PubMed ID: 34764009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of Life and Real-time Patient Experience During Neoadjuvant Therapy: A Prospective Cohort Study.
    Shannon AH; Sarna A; Bressler L; Monsour C; Palettas M; Huang E; D'Souza DM; Kneuertz PJ; Ejaz A; Pawlik TM; Santry H; Cloyd JM
    Ann Surg; 2024 May; 279(5):850-856. PubMed ID: 37641957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma.
    Cloyd JM; Shen C; Santry H; Bridges J; Dillhoff M; Ejaz A; Pawlik TM; Tsung A
    J Natl Compr Canc Netw; 2020 May; 18(5):556-563. PubMed ID: 32380462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Quality of Online Information Regarding Neoadjuvant Therapy for Pancreatic Cancer.
    Stevens L; Guo M; Brown ZJ; Ejaz A; Pawlik TM; Cloyd JM
    J Gastrointest Cancer; 2023 Sep; 54(3):890-896. PubMed ID: 36327090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing treatment burden during neoadjuvant therapy for patients with gastrointestinal cancer: A mixed methods analysis.
    Bath NM; Sarna A; Palettas M; Monsour C; Stevens L; Santry H; Ejaz A; Kim A; Pawlik T; Cloyd JM
    J Surg Oncol; 2023 Aug; 128(2):393-401. PubMed ID: 37079430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research.
    Cloyd JM; Tsung A; Hays J; Wills CE; Bridges JF
    World J Gastroenterol; 2020 Jan; 26(4):375-382. PubMed ID: 32063686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 15. Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy.
    Laitinen I; Sand J; Peromaa P; Nordback I; Laukkarinen J
    Pancreatology; 2017; 17(3):445-450. PubMed ID: 28274687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment.
    Nipp RD; Zanconato A; Zheng H; Ferrone CR; Lillemoe KD; Wo JY; Hong TS; Clark JW; Ryan DP; Fernández-Del Castillo C
    Pancreas; 2017 Feb; 46(2):183-189. PubMed ID: 27846142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supportive care in pancreatic ductal adenocarcinoma.
    Laquente B; Calsina-Berna A; Carmona-Bayonas A; Jiménez-Fonseca P; Peiró I; Carrato A
    Clin Transl Oncol; 2017 Nov; 19(11):1293-1302. PubMed ID: 28612201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
    Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.